



May 25, 2023

**The Manager – Listing
National Stock Exchange of India Limited,**
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

**The Manager – Listing
BSE Limited,**
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : Investor Presentation
Stock Code : BSE – 539787, NSE – HCG

We wish to inform you that the Board of Directors of the Company, at their meeting held on May 25, 2023, *inter alia*, has approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2023 (“Financial Results”).

In this respect, we enclose herewith the Presentation on the Financial Results of the Company for the quarter and year ended March 31, 2023.

Request you to take this on record.

Thanking you,

For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a.

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



HEALTHCARE GLOBAL ENTERPRISES LIMITED



INVESTOR PRESENTATION
May 2023



SAFE HARBOR



This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful.

This presentation has been prepared by **HealthCare Global Enterprises Limited (the "Company")**. These materials are not for publication or distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). These materials are not an offer of securities for sale into the United States, Canada or Japan or any other jurisdiction. Any securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of any securities of the Company is being made in the United States.

The information contained in this presentation is for information purposes only and does not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction.

No person accepts any liability whatsoever for any loss howsoever arising from the use of this document or of its contents or otherwise arising in connection therewith. The information set out herein may be subject to updating, completion, revision, verification and amendment without notice and such information may change materially. Financial information contained in this presentation has been derived from the restated consolidated and standalone financial statements of the Company and have been rounded off to the next integer, except percentages which have been rounded off to one decimal point.

This presentation contains certain "forward looking statements". Forward-looking statements are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments.

This presentation includes certain industry data and projections that have been obtained from industry publications and surveys. Industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance that the information is accurate or complete. Neither the Company nor any of its advisors or representatives have independently verified any of the data from third-party sources or ascertained the underlying economic assumptions relied upon therein. No representation or claim is made that the results or projections contained in this presentation will actually be achieved. All industry data and projections contained in this presentation are based on data obtained from the sources cited and involve significant elements of subjective judgment and analysis, which may or may not be correct. For the reasons mentioned above, you should not rely in any way on any of the projections contained in this presentation for any purpose. No responsibility or liability whatsoever is undertaken for the contents hereof.

This presentation is based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.



SUBASENI LENKA, CANCER WINNER

“ I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time ”

Q4 & FY23 FINANCIAL & OPERATIONAL HIGHLIGHTS



Clinical Highlights & Recognitions

Clinical Highlights

- ❖ Launch of **"CELL SEARCH"** circulating **Tumor Cell (CTC) TESTING**. Cell Search is the first and only system which received FDA approval for the precise enumeration of Circulating tumor Cells in patients' blood for diagnostic purposes - First in India
 - ❖ Early detection and Screening
 - ❖ Informed Patient Care Decisions
 - ❖ Stratification and therapeutic intervention
 - ❖ Real-time treatment monitoring
- ❖ **Research and Academics:**
 - ❖ Prestigious **Lee Yung grant from Trinity Hall**, University of Cambridge awards conferred to 2 candidates (Dr Vishal Rao & Swetha Kannan)
 - ❖ Published **85 articles in high impact journals** during Q4FY23. **Total indexed publications 822**
 - ❖ **~30 clinical trials** ongoing across the Network
 - ❖ Total allied health programs is **~95**
 - ❖ Total Nursing Programs **~180**
 - ❖ Total DNB residents across the network is **~369 currently**

Recognitions

- ❖ Dr Joydeep Chakrabartty, HCG Kolkata was selected as the **Country Advisor for East India by the Royal College of Pathologists (RCPath)**
- ❖ Dr. Gaurav Medikeri has **authored a chapter in the book Atlas of Frontal Sinus Surgery**, Springer Healthcare IME Springer Healthcare India named "Training in frontal sinus surgery".
- ❖ Dr Nishit Ojha, Dr Amey Panchal & Dr Sachin Jadhav identified a new mutation **"Whole transcriptome sequencing reveals HOXD11-AGAP3, a novel fusion transcript in the Indian acute leukemia cohort"**
- ❖ Dr Trinanjan Basu for the **poster presentation of Prostate SBRT** at the Radiosurgery Annual Meeting in Orlando, Florida March 2023



Genomics - Future for Cancer Care*

HCG is First in Asia to complete ~105 Clinical runs (1000+patients) of Comprehensive Genomic Profiling (CGP)

1,000+ Patient samples processed with TSO500

1291+ Total number of genomic alterations detected in cohort

54 Number of RNA alterations detected in cohort

77% Patients with actionable and prognostic genetic alterations

Up to 80% Assigned to approved therapies (for specific indications)


Up to 25% Change in clinical management (for specific indications)

*Abstract accepted for ASCO 2023
Poster accepted for ESMO-Lung-2023
Journal Publication - 2+



Financial Highlights Q4 FY23


REVENUE




REVENUE - HCG Centers⁽¹⁾




REVENUE - Milann Centers[^]




ADJUSTED EBITDA




ADJUSTED EBITDA MARGIN



PROFIT AFTER TAX² (Pre-IND AS)



PROFIT AFTER TAX² (Post-IND AS)



Adjusted EBITDA excludes

- Impact of ESOPs cost of INR 15 mn for Q4FY23 and INR 20 mn in Q4FY22
- Impact of one-time consulting fees for strategy work for a period of 12-18 months. Cost of one-time consulting fees stands at INR 53 mn for Q4FY23 & INR 25 mn for Q4FY22

1. 22 comprehensive cancer centers, 3 multispecialty hospitals




Financial Highlights FY23


REVENUE




REVENUE - HCG Centers⁽¹⁾




REVENUE - Milann Centers[^]




ADJUSTED EBITDA




ADJUSTED EBITDA MARGIN



PROFIT AFTER TAX² (Pre-IND AS)



PROFIT AFTER TAX² (Post-IND AS)



Adjusted EBITDA excludes

- Impact of ESOPs cost of INR 64 mn for FY23 and INR 28 mn in FY22

- Impact of one-time consulting fees for strategy work for a period of 12-18 months. Cost of one-time consulting fees stands at INR 157 mn for FY23 & INR 45 mn for FY22


1. 22 comprehensive cancer centers, 3 multispecialty hospitals

2. PAT for FY23 is pre-exceptional items




Improved Performance Leading to Profitability


Revenue
(INR mn)




EBITDA
(INR mn)



PAT
(INR mn)
(Post IND-AS 116)



PAT
(INR mn)
(Pre IND-AS 116)



(1) Includes loss due to exceptional items of INR 847 mn


(2) Includes gain on exceptional items of INR 1,401 mn



Growth Across HCG Centers


Matured Centers

~1.4x growth in last 9 quarters




Emerging Centers ^

~2.0x growth in last 9 quarters




Matured Centers

~1.5x growth in last 9 quarters



Emerging Centers ^

On a positive trajectory



REVENUE #

EBITDA *



Strong Operating Metrics with Significant Capacity Headroom

Key Driver	Metric Indicator	% Revenue	Q4'22	Q4'23	FY'22	FY'23
# New Registrations ('000)	Lead indicator of Volume Growth ; key operating metric tracked by HCG; has correlation to out-patient revenue	21% ⁽¹⁾	18	20	68	80
Chemo Sessions Administered ('000)	Key indicator for Medical Oncology ; procedures are primarily day care oriented with no capacity constraint	37%	28	34	104	133
LINAC - Capacity Utilization ⁽²⁾	Key indicator for Radiation Oncology ; availability of LINACs is the only capacity constraint ; further augmenting capacity by 20%	18%	60%	65%	59%	66%
In-Patient Bed Occupancy ⁽³⁾	Indicator for Surgical Oncology ; with decreasing ALOS and flexibility to add balance non-operational capacity beds, not a capacity constraint operationally ; additional 214 beds available to be made operational	24%	54%	59%	53%	60%

(1) Revenue % for out-patient and others only; (2) Total radiation patients treated stands at ~ 5,100 in Q4'23 & ~21,000 in FY23; (3) Total in-patient bed capacity for oncology is 1,415 beds and operational beds is 1,228. This excludes 294 day care beds and 338 multispecialty beds



HCG - Q4FY23 Operational Metrics[#]



TOTAL AOR (%)	MATURED CENTERS AOR (%)	EMERGING CENTERS AOR ^{^*} (%)	MATURED CENTERS ROCE (%)
65.1% <i>59.9% in Q4FY22</i> ↑ 516 bps	64.8% <i>59.1% in Q4FY22</i> ↑ 572 bps	65.7% <i>52.9% in Q4FY22</i> ↑ 1,281 bps	22.9% <i>18.7% in Q4FY22</i> ↑ 420 bps <i>ROCE pre-corporate allocations stands at 25.2%</i>
TOTAL ARPOB (Rs.)	MATURED CENTERS ARPOB (Rs.)	EMERGING CENTERS ARPOB [^] (Rs.)	EMERGING CENTERS [^] ROCE (%)
39,864 <i>38,596 in Q4FY22</i> ↑ 3.3%	41,394 <i>39,753 in Q4FY22</i> ↑ 4.1%	36,063 <i>35,474 in Q4FY22</i> ↑ 1.7%	-3.6% <i>-8.3% in Q4FY22</i> ↑ 470 bps <i>ROCE pre-corporate allocations stands at -2.4%</i>

[^]New Center represents centers operational after 2017

^{*}75% of the capacity beds are operational; AOR 50% on capacity beds

[#]Excl. Fertility

Existing Centers Operational beds: 1312 + New Centers Operational Beds: 521 = Total 1,833 Operational Beds

ROCE is annualized for Q4FY23 & Q4FY22 adjusted for ESOP & One time value creation cost



HCG - FY23 Operational Metrics[#]



TOTAL AOR (%)	MATURED CENTERS AOR (%)	EMERGING CENTERS AOR ^{^*} (%)	MATURED CENTERS ROCE (%)
65.4% 58.2% in FY22 ↑ 726 bps	64.3% 58.8% in FY22 ↑ 550 bps	68.5% 54.2% in FY22 ↑ 1,429 bps	22.0% 16.3% in FY22 ↑ 570 bps <i>ROCE pre-corporate allocations stands at 25.5%</i>
TOTAL ARPOB (Rs.)	MATURED CENTERS ARPOB (Rs.)	EMERGING CENTERS ARPOB [^] (Rs.)	EMERGING CENTERS [^] ROCE (%)
38,042 37,841 in FY22 ↑ 0.5%	40,455 38,181 in FY22 ↑ 6.0%	32,215 36,836 in FY22 ↓ -12.5%	-4.0% -7.9% in FY22 ↑ 390 bps <i>ROCE pre-corporate allocations stands at -1.7%</i>

[^]New Center represents centers operational after 2017

^{*}75% of the capacity beds are operational; AOR 50% on capacity beds

[#]Excl. Fertility

Existing Centers Operational beds: 1312 + New Centers Operational Beds: 521 = Total 1,833 Operational Beds

ROCE is adjusted for ESOP & One time value creation cost



HCG - Cluster Wise Revenue Break Up[#]

CLUSTER	Q4FY23	Q4FY22	Y-o-Y	FY23	FY22	Y-o-Y
KARNATAKA	1,498	1,262	19%	5,692	4,748	20%
GUJARAT	1,084	913	19%	4,163	3,518	18%
MAHARASHTRA*	627	529	19%	2,408	2,275	6%
EAST INDIA	479	301	59%	1,688	1,168	44%
ANDHRA PRADESH	289	281	3%	1,204	1,047	15%
TAMIL NADU	73	60	21%	278	231	20%
NORTH INDIA	176	129	36%	757	343	121%
AFRICA	33	13	158%	91	27	241%
TOTAL	4,259	3,488	22%	16,281	13,357	22%

KOLKATA

RAJKOT

RANCHI

JAIPUR

CUTTACK

142% Y-o-Y for
Q4FY23

58% Y-o-Y
For Q4FY23

51% Y-o-Y
For Q4FY23

37% Y-o-Y
For Q4FY23

32% Y-o-Y
For Q4FY23

[#]Excl. Fertility Revenue *FY23 revenue growth for Maharashtra excl. vaccination at 15.3%



Milann - Implementing Strategic Initiatives


Particulars	Q4FY23	Q4FY22*	Growth Y-o-Y	FY23	FY22*	Growth Y-o-Y
New Registrations	1,286	1,651	-22.1%	5,265	4,633	13.6%
IVF Cycles	461	497	-7.2%	1,936	1,747	10.8%
Revenues (Rs. Mn.)	158	158	0.2%	663	621	6.8%

Continuous focus on strengthening clinical talent

- Lower volume on YoY basis is led by regulations around surrogacy.
- Regulation has eased out in Karnataka & the volumes are expected to pick up

Looking to focus on market leadership in Bangalore and scaling up North India centers in near term

BENGALURU (5 Centers)



NORTH INDIA (2 Centers)



1. Centers in operation prior to April 1, 2016, i.e., Shivananda, JP Nagar and Indiranagar

*Incl. Vaccination revenue



Capital Expenditure & Net Debt

CAPITAL EXPENDITURE (Rs. Mn.)

HCG CENTERS	FY23	FY22
Matured Centers	1,093.7	458.4
Emerging Centers	163.3	245.8
TOTAL CAPEX	1,257.0	704.2

ONGOING CAPEX (Rs. Mn.)

Sr. No	Particulars	Capex incurred till 31 st March 2023	Expected Capex for FY24	Total Planned Capex	Expected date of Operations
1	Ahmedabad – Phase II	158	636	852	Q1 FY25
2	Whitefield (Extension of Bangalore - COE)	10	200	250	Q3 FY25

NET DEBT (Rs. Mn.)

NET DEBT	31 st March 2023	31 st Mar 2022
Bank Debt ⁽¹⁾	3,733	3,543
Vendor Finance ⁽²⁾	223	333
Other Debt	8	34
Less: Cash & Cash Equivalents ⁽³⁾	1,983	2,008
NET DEBT	1,980	1,901
Capital Leases: Ind AS116	5,019	5,070
Net Debt (Incl. Leases)	6,999	6,972


1. Bank debt: Net of Bank balance held as margin money of INR 147 Mn and investment in fixed deposits of INR -17.00 Mn (Margin money value reclassified to other deposit) as of 31st Mar -23, INR 161 Mn and investment in fixed deposits of INR 33 Mn as of 31st Mar - 22. The unamortized portion of processing fees amounting to INR 29.37 Mn as on 31st Mar - 23 & INR 32 Mn as on 31st Mar -22 netted off against Bank Debt.

2. Vendor Finance; Includes Forex reinstatement of INR (1.46) Mn as of 31st Mar-23 and Forex reinstatement of INR (14.00) Mn as of 31st Mar -22

3. Cash and cash equivalents: Includes investment in mutual funds of INR 16 Mn as at 31st Mar -23 and of INR 16 Mn as at 31st Mar - 22



Platform for Attractive Returns with Efficient Capital Allocation and Asset Light Expansion



*ROCE has been calculated for only Oncology adjusted for ESOP & One time value creation cost



Q4 & FY23 Consolidated Profit & Loss Account

Profit and Loss (in Rs. Mn.)	Q4 FY23	Q4 FY22	Y-o-Y	Q3 FY23	Q-o-Q	FY23	FY22	Y-o-Y
Revenues from Operations	4,410	3,639		4,239		16,914	13,948	
Income from Govt. Grant	7	7		8		30	30	
Total Revenue from Operations	4,417	3,646	21%	4,247	4%	16,944	13,978	21%
Cost of Goods Sold	1,164	910		1,075		4,241	3,549	
Employee Cost	674	587		674		2,687	2,308	
Medical Consultancy Charges	913	843		884		3,561	2,958	
Other Expenses	836	630		802		3,248	2,709	
Adjusted EBITDA	831	676	23%	812	2%	3,208	2,453	31%
Adjusted EBITDA Margin (%)	18.8%	18.5%	26 bps	19.1%	-31 bps	18.9%	17.6%	138 bps
One time value creation cost	53	25		39		157	45	
ESOP's	15	20		18		64	28	
Reported EBIDTA	763	632	21%	755	1%	2,987	2,380	26%
Reported EBITDA Margin (%)	17.3%	17.3%	-4 bps	17.8%	-50 bps	17.6%	17.0%	60 bps
Depreciation	422	411		408		1,635	1,583	
Other Income	47	30		37		132	127	
EBIT	388	251		384		1,484	924	
Finance Cost	256	241		271		1,035	978	
Extraordinary Items	0	0		0		0	946	
Share in Profit/(loss) in JV and Associates	0	0		0		0	0	
Profit before Tax	131	9		113		449	878	
Taxes, Other Comprehensive Income & Minority Interest	48	-51		38		155	340	
Profit After Tax	83.7	59.9	40%	75	12%	293.4	537.3*	-45%
PAT Margin (%)	1.9%	1.6%	25 bps	1.8%	12 bps	1.7%	3.8%	-211 bps



Consolidated Balance Sheet

Balance Sheet - Equity & Liabilities (in Rs. Mn.)	Mar-23	Mar-22
Equity Share Capital	1,391	1,390
Other Equity	7,214	7,313
Equity Attributable To Equity Holders Of The Company	8,605	8,703
Non-Controlling Interests	89	134
Total Equity	8,694	8,837
Non-Current Liabilities		
Financial Liabilities		
Borrowings	3,628	3,629
Lease Liabilities	4,531	4,659
Other Financial Liabilities	0	0
Provisions	132	105
Other Non-Current Liabilities	359	255
Deferred Tax Liabilities (Net)	124	13
Total Non-Current Liabilities	8,774	8,661
Current Liabilities		
Financial Liabilities		
Borrowings	365	448
Lease Liabilities	488	411
Trade Payables	0	0
Total Outstanding Dues Of Micro Enterprises And Small Enterprises	50	20
Total Outstanding Dues Of Creditors Other Than Micro Enterprises And Small Enterprises	2,435	1,919
Other Financial Liabilities	1,404	936
Other Current Liabilities	755	785
Provisions	171	173
Income Tax Liabilities (Net)	25	5
Total Current Liabilities	5,693	4,698
Total Equity And Liabilities	23,160	22,195

Balance Sheet - Assets (Rs. Mn.)	Mar-23	Mar-22
Non-Current Assets		
Property, Plant And Equipment	9,718	9,315
Capital Work in Progress	182	217
Rights-of-use Assets	3,813	4,045
Goodwill	1,812	1,813
Other Intangible Assets	187	298
Intangible Assets Under Development		
Financial Assets		
Investments	97	88
Loans Receivable	0	0
Other Financial Assets	543	546
Deferred Tax Assets (Net)	53	60
Income Tax Assets (Net)	574	459
Other Non-Current Assets	378	331
Total Non-Current Assets	17,357	17,172
Current Assets		
Inventories	383	300
Financial Assets		
Trade Receivables	3,025	2,175
Cash And Cash Equivalents	1,746	1,975
Bank Balances Other Than Cash And Cash Equivalents	219	0
Loans	18	16
Other Financial Assets	74	341
Other Current Assets	339	217
Total Current Assets	5,803	5,024
Total Assets	23,160	22,195



Consolidated Cash Flow Statement

Cash Flow Statement (in Rs. Mn)	Mar-23	Mar-22
Net Profit Before Tax	449	878
Adjustments For: Non - Cash Items / Other Investment Or Financial Items	2,753	1,666
Operating Profit Before Working Capital Changes	3,201	2,543
Changes In Working Capital	-459	-105
Cash Generated From Operations	2,743	2,438
Direct Taxes Paid (Net Of Refund)	-227	-237
Net Cash From Operating Activities	2,516	2,201
Net Cash From Investing Activities	-1,330	1,246
Net Cash From Financing Activities	-1,401	-1,549
Net Increase/Decrease In Cash And Cash Equivalents	-215	1,898
Add: Cash & Cash Equivalents At The Beginning Of The Period	1,927	29
Cash & Cash Equivalents At The End Of The Period	1,712	1,927



SHANKAR, CANCER WINNER

“ The days I was at HCG,
I felt like I was sleeping at
home. They never stop caring
for you. The doctors and
nurses are always finding ways
to make this difficult journey
as comfortable as possible ”

HISTORICAL FINANCIAL HIGHLIGHTS



Historical Profit & Loss Account

Profit and Loss (in Rs. Mn.)	FY23	FY22	FY21	FY20	FY19	CAGR
Revenues from Operations	16,914	13,948	10,092	10,923	9,760	
Income from Govt. Grant	30	30	43	33	27	
Total Revenue from Operations	16,944	13,978	10,134	10,956	9,787	15%
Costs of Goods Sold	4,241	3,549	3,632	3,645	3,581	
Employee Cost	2,687	2,337	1,959	2,080	1,845	
Medical Consultancy Charges	3,561	2,958	2,218	2,451	2,114	
Other Expenses	3,248	2,754	2,289	2,305	2,389	
EBITDA	3,208	2,380	1,266	1,722	1,252	24%
EBITDA Margin (%)	18.9%	17.0%	12.5%	15.7%	12.8%	
Depreciation	1,635	1,583	1,592	1,485	851	
Other Income	132	127	170	70	74	
EBIT	1,484	924	-157	307	475	32%
Finance Cost	1,035	978	1,192	1,377	699	
Extraordinary Items	0	946	-847	0	0	
Share in Profit/(loss) in JV and Associates	0	-14	-4	-123	-110	
Profit before Tax	449	878	-2,199	-1,193	-334	NA
Taxes, Other Comprehensive Income & Minority Interest	155	340	-264	-131	-86	
Profit After Tax	293	538	-1,935	-1,062	-248	NA
PAT Margin (%)	1.7%	3.8%	-19.1%	-9.7%	-2.5%	
EPS (in INR)	0	4.1	-16.9	-2.9	-2.8	



Historical Balance Sheet

Balance Sheet - Equity & Liabilities (in Rs. Mn.)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Equity Share Capital	1,391	1,390	1,254	887	879
Other Equity	7,214	7,313	5,718	2,926	3,933
Equity Attributable To Equity Holders Of The Company	8,605	8,703	6,972	3,813	4,811
Non-Controlling Interests	89	134	168	385	619
Total Equity	8,694	8,837	7,140	4,198	5,430
Non-Current Liabilities					
Financial Liabilities	0	0	0	0	0
Borrowings	3,628	3,629	3,462	5,296	4,666
Lease Liabilities	4,531	4,659	4,693	6,092	202
Other Financial Liabilities	0	255	0	624	0
Provisions	132	105	86	73	56
Other Non-Current Liabilities	359	0.0	280	422	318
Deferred Tax Liabilities (Net)	124	13	43	70	43
Total Non-Current Liabilities	8,774	8,661	8,564	12,576	5,285
Current Liabilities					
Financial Liabilities	0	0	0	0	0
Borrowings	365	448	670	937	648
Lease Liabilities	488	411	365	215	0.0
Trade Payables	0	0	0	0	0
Total Outstanding Dues Of Micro Enterprises And Small Enterprises	50	20	3	0	0.0
Total Outstanding Dues Of Creditors Other Than Micro Enterprises And Small Enterprises	2,435	1,919	1,452	1,536	1,683
Other Financial Liabilities	1,404	936	1,428	2,654	2,557
Other Current Liabilities	755	785	626	305	337
Provisions	171	173	104	91	63
Income Tax Liabilities (Net)	25	5	4	22	12
Total Current Liabilities	5,693	4,698	4,653	5,758	5,300
Total Equity And Liabilities	23,160	22,195	20,356	22,532	16,015



Historical Balance Sheet

Balance Sheet - Assets (in Rs. Mn.)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Non-Current Assets					
Property, Plant And Equipment	9,718	9,315	8,531	9,271	8,026
Capital Work in Progress	182	217	300	461	1,440
Rights-of-use Assets	3,813	4,045	4,114	5,776	0
Goodwill	1,812	1,813	963	1,093	1,093
Other Intangible Assets	187	298	215	320	96
Intangible Assets Under Development		30	206	268	469
Financial Assets		0	0	0	0
Investments	97	58	57	74	68
Loans Receivable	0	0	451	516	476
Other Financial Assets	543	546	168	222	196
Deferred Tax Assets (Net)	53	60	343	261	311
Income Tax Assets (Net)	574	459	426	818	307
Other Non-Current Assets	378	331	232	414	742
Total Non-Current Assets	17,357	17,172	16,007	19,494	13,222
Current Assets		0	0	0	0
Inventories	383	300	211	233	285
Financial Assets		0	0	0	0
Trade Receivables	3,025	2,175	1,866	1,857	1,646
Cash And Cash Equivalents	1,746	1,975	300	318	280
Bank Balances Other Than Cash And Cash Equivalents	219	0	109	3	44
Loans	18	16	93	54	40
Other Financial Assets	74	341	1,546	275	211
Other Current Assets	339	217	225	300	288
Total Current Assets	5,803	5,024	4,350	3,038	2,793
Total Assets	23,160	22,195	20,356	22,532	16,015



Historical Cash Flow Statement

Cash Flow Statement (in Rs. Mn)	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Net Profit Before Tax	449	878	-2,287	-1,193	-334
Adjustments For: Non - Cash Items / Other Investment Or Financial Items	2,753	1,666	3,619	2,988	2,463
Operating Profit Before Working Capital Changes	3,201	2,543	1,333	1,795	2,130
Changes In Working Capital	-459	-105	-507	-226	-774
Cash Generated From Operations	2,743	2,438	826	1,569	1,355
Direct Taxes Paid (Net Of Refund)	-227	-237	380	-267	370
Net Cash From Operating Activities	2,516	2,201	1,205	1,301	985
Net Cash From Investing Activities	-1,330	1,246	-1,711	-1,014	-2,382
Net Cash From Financing Activities	-1,401	-1,549	1,123	-584	835
Net Increase/Decrease In Cash And Cash Equivalents	-215	1,898	617	-297	-562
Add: Cash & Cash Equivalents At The Beginning Of The Period	1,927	29	-588	-291	271
Cash & Cash Equivalents At The End Of The Period	1,712	1,927	29	-588	-291



THANK YOU

Company: HealthCare Global Enterprises Limited



CIN: L15200KA1998PLC023489

For updates and specific queries, please visit
www.hcgoncology.com
or feel free to contact investors@hcgoncology.com

Investor Relation Advisors: Strategic Growth Advisors

SGA Strategic Growth Advisors

CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Ayush Haria
sagar.shroff@sgapl.net / ayush.harria@sgapl.net
Tel: +91 98205 19303 / +91 98204 62966

© 2022 HealthCare Global Enterprises Limited., All Rights Reserved.

HCG Logo is trademark of HealthCare Global Enterprises Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation.

This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.